kathryn balmanno
kathryn balmanno
Verified email at babraham.ac.uk
TitleCited byYear
Activation of the ERK1/2 signaling pathway promotes phosphorylation and proteasome-dependent degradation of the BH3-only protein, Bim
R Ley, K Balmanno, K Hadfield, C Weston, SJ Cook
Journal of Biological Chemistry 278 (21), 18811-18816, 2003
6432003
Tumour cell survival signalling by the ERK1/2 pathway
K Balmanno, SJ Cook
Cell death and differentiation 16 (3), 368, 2009
3962009
Sustained MAP kinase activation is required for the expression of cyclin D1, p21Cip1 and a subset of AP-1 proteins in CCL39 cells
K Balmanno, SJ Cook
Oncogene 18 (20), 3085, 1999
2681999
Extracellular signal-regulated kinases 1/2 are serum-stimulated “BimEL kinases” that bind to the BH3-only protein BimEL causing its phosphorylation and turnover
R Ley, KE Ewings, K Hadfield, E Howes, K Balmanno, SJ Cook
Journal of Biological Chemistry 279 (10), 8837-8847, 2004
2282004
Activation of ERK1/2 by ΔRaf-1: ER* represses Bim expression independently of the JNK or PI3K pathways
CR Weston, K Balmanno, C Chalmers, K Hadfield, SA Molton, R Ley, ...
Oncogene 22 (9), 1281, 2003
2042003
ERK1/2‐dependent phosphorylation of BimEL promotes its rapid dissociation from Mcl‐1 and Bcl‐xL
KE Ewings, K Hadfield‐Moorhouse, CM Wiggins, JA Wickenden, ...
The EMBO journal 26 (12), 2856-2867, 2007
1822007
Amplification of the driving oncogene, KRAS or BRAF, underpins acquired resistance to MEK1/2 inhibitors in colorectal cancer cells
AS Little, K Balmanno, MJ Sale, S Newman, JR Dry, M Hampson, ...
Sci. Signal. 4 (166), ra17-ra17, 2011
1722011
Carboplatin pharmacokinetics in children: the development of a pediatric dosing formula. The United Kingdom Children's Cancer Study Group.
DR Newell, AD Pearson, K Balmanno, L Price, RA Wyllie, M Keir, ...
Journal of clinical oncology 11 (12), 2314-2323, 1993
1471993
Intrinsic resistance to the MEK1/2 inhibitor AZD6244 (ARRY‐142886) is associated with weak ERK1/2 signalling and/or strong PI3K signalling in colorectal cancer cell lines
K Balmanno, SD Chell, AS Gillings, S Hayat, SJ Cook
International journal of cancer 125 (10), 2332-2341, 2009
1342009
Apoptosis and autophagy: BIM as a mediator of tumour cell death in response to oncogene‐targeted therapeutics
AS Gillings, K Balmanno, CM Wiggins, M Johnson, SJ Cook
The FEBS journal 276 (21), 6050-6062, 2009
1062009
ERK1/2 and p38 cooperate to induce a p21CIP1-dependent G1 cell cycle arrest
DE Todd, RM Densham, SA Molton, K Balmanno, C Newson, CR Weston, ...
Oncogene 23 (19), 3284, 2004
1042004
Tumour cell responses to new fibroblast growth factor receptor tyrosine kinase inhibitors and identification of a gatekeeper mutation in FGFR3 as a mechanism of acquired resistance
V Chell, K Balmanno, AS Little, M Wilson, S Andrews, L Blockley, ...
Oncogene 32 (25), 3059, 2013
902013
Colorectal cancer cells with the BRAFV600E mutation are addicted to the ERK1/2 pathway for growth factor-independent survival and repression of BIM
JA Wickenden, H Jin, M Johnson, AS Gillings, C Newson, M Austin, ...
Oncogene 27 (57), 7150, 2008
712008
Adaptation to mTOR kinase inhibitors by amplification of eIF4E to maintain cap-dependent translation
CL Cope, R Gilley, K Balmanno, MJ Sale, KD Howarth, M Hampson, ...
J Cell Sci 127 (4), 788-800, 2014
702014
ΔMEKK3:ER* activation induces a p38α/β2-dependent cell cycle arrest at the G2 checkpoint
AP Garner, CR Weston, DE Todd, K Balmanno, SJ Cook
Oncogene 21 (53), 8089, 2002
682002
RNA-binding proteins ZFP36L1 and ZFP36L2 promote cell quiescence
A Galloway, A Saveliev, S Łukasiak, DJ Hodson, D Bolland, K Balmanno, ...
Science 352 (6284), 453-459, 2016
592016
Thrombin inhibits Bim (Bcl-2-interacting mediator of cell death) expression and prevents serum-withdrawal-induced apoptosis via protease-activated receptor 1
CJ Chalmers, K Balmanno, K Hadfield, R Ley, SJ Cook
Biochemical Journal 375 (1), 99-109, 2003
592003
The duration of ERK1/2 activity determines the activation of c-Fos and Fra-1 and the composition and quantitative transcriptional output of AP-1
CJ Chalmers, R Gilley, HN March, K Balmanno, SJ Cook
Cellular signalling 19 (4), 695-704, 2007
542007
Clinical pharmacokinetic and pharmacodynamic studies with the nonclassical antifolate thymidylate synthase inhibitor 3, 4-dihydro-2-amino-6-methyl-4-oxo-5-(4-pyridylthio …
I Rafi, GA Taylor, JA Calvete, AV Boddy, K Balmanno, N Bailey, M Lind, ...
Clinical cancer research 1 (11), 1275-1284, 1995
491995
Regulation of cell cycle re-entry by growth, survival and stress signalling pathways
SJ Cook, K Balmanno, A Garner, T Millar, C Taverner, D Todd
Biochemical Society Transactions 28 (1), 3-3, 2000
422000
The system can't perform the operation now. Try again later.
Articles 1–20